Novartis, AstraZeneca, CPI and UK Research and Innovation to revolutionise the manufacturing of oligonucleotide therapies – at LondonEast-UK!

The Medicines Manufacturing Innovation Centre has just launched a collaboration that will look to develop a scalable, sustainable and more cost-effective medicines manufacturing process for oligonucleotides: short strands of synthetic DNA or RNA.

This collaboration with AstraZeneca, Exactmer, Novartis and UK Research & Innovation aims to make the UK the first country in the world to deliver this pioneering production process at a large scale. The collaboration will enable the partners to utilise their combined expertise across scale-up, analytics and process development with the goal of transforming the oligonucleotide supply chain.

Inclisiran, a small interfering RNA used in the treatment of atherosclerotic cardiovascular disease (ASCVD), would be the first medicine produced at scale as a result of this collaboration.

Initial activities will take place at Exactmer’s facilities in The Cube at LondonEast-UK in Dagenham, London, with the large scale later phases taking place at the Medicines Manufacturing Innovation Centre in Renfrewshire, Scotland.

Tony Barry, Chief Executive of BD Group, the owner of LondonEast-UK business and science park, commented, “LondonEast-UK has a rich scientific history, having previously been home to Sanofi, the multinational pharmaceutical company, so it is fantastic to see it continuing to be a home to scientific innovation and excellence.”

Click here to find out more.